High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article
120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
Fernandez-Martinez, A., Pascual, T., Singh, B., Nuciforo, P., Hoadley, K.A., Rashid, N.U., Spears, P.A., Chic, N., Krop, I., Hillman, D., Partridge, A., Prat, A., Carey, L.A., Perou, C.M.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al
McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article